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ABSTRACT
Epigenetic regulatory mechanisms play a central role in controlling gene expression 
during development, cell differentiation and tumorigenesis. Monoubiquitination of 
histone H2B is one epigenetic modification which is dynamically regulated by the 
opposing activities of specific ubiquitin ligases and deubiquitinating enzymes (DUBs). 
The Ubiquitin-specific Protease 22 (USP22) is the ubiquitin hydrolase component of the 
human SAGA complex which deubiquitinates histone H2B during transcription. Recently, 
many studies have investigated an oncogenic potential of USP22 overexpression. 
However, its physiological function in organ maintenance, development and its cellular 
function remain largely unknown. A previous study reported embryonic lethality in 
Usp22 knockout mice. Here we describe a mouse model with a global reduction of 
USP22 levels which expresses the LacZ gene under the control of the endogenous 
Usp22 promoter. Using this reporter we found Usp22 to be ubiquitously expressed in 
murine embryos. Notably, adult Usp22lacZ/lacZ displayed low residual Usp22 expression 
levels coupled with a reduced body size and weight. Interestingly, the reduction of 
Usp22 significantly influenced the frequency of differentiated cells in the small intestine 
and the brain while H2B and H2Bub1 levels remained constant. Taken together, we 
provide evidence for a physiological role for USP22 in controlling cell differentiation 
and lineage specification.
INTRODUCTION
Proper regulation of gene expression patterns is 
crucial for embryonic development, cell fate determination 
and differentiation [1–3]. Differentiation-associated 
changes in transcription are closely associated with 
alterations in epigenetic modifications such as methylation, 
acetylation, phosphorylation and monoubiquitination 
of histones [4]. In humans the obligate heterodimeric 
RNF20/RNF40 complex functions as the E3 ubiquitin 
ligase responsible for the monoubiquitination of histone 
H2B (H2Bub1) [5]. Previous studies revealed an essential 
role of RNF20 and RNF40 in controlling the expression 
of a subset of genes [6, 7] and a particular role in cell 
differentiation [8, 9]. Ubiquitination is removed from 
H2B via the deubiquitinating module (mDUB) of the 
SAGA (Spt–Ada–Gcn5 acetyltransferase) transcriptional 
coactivator complex. Ubiquitin-specific Protease 22 
(USP22) is the deubiquitinating subunit of the SAGA 
mDUB complex [10] and has been reported to affect 
transcription by the deubiquitination of histones H2A and 
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H2B [11–14]. Additionally, USP22 functions to stabilize 
specific proteins via the removal of ubiquitin moieties, 
thereby preventing proteasomal degradation [15–25]. 
Notably, in addition to H2B, the histone deacetylase Sirt1 
has been reported to be a central deubiquitination target of 
USP22 [22]. USP22 was also reported to control cell cycle 
progression since its depletion resulted in the induction 
of a G1 cell cycle arrest in colorectal cancer cells in vitro 
[26]. Consistent with this effect, USP22 was implicated in 
the expression of MYC target genes such as Cyclin D1 and 
its presence is required for MYC-mediated transformation 
in non-small cell lung carcinoma cells [10].
A number of studies have suggested an important 
function for USP22 during tumorigenesis and/or tumor 
progression. Notably, USP22 was initially reported as a 
member of an 11-gene “death from cancer” gene expression 
signature which identified tumors displaying a stem cell-like 
gene expression profile characterized by high malignancy 
and metastatic dissemination [27]. Since then USP22 has 
been reported to stabilize some cancer-associated proteins 
and increased expression was correlated to poor prognosis 
[15, 16, 19, 21–23, 25]. In particular, a role of USP22 has 
been suggested in non-small cell lung cancer [15, 21, 28], 
gastric carcinoma [29], glioma [30], pancreatic cancer 
[18, 28], breast [31] and colorectal cancer [25, 32, 33]. 
While some putative USP22 targets have been identified, 
the exact molecular mechanisms by which USP22 functions 
and its physiological role remain to be elucidated.
Initial indications that USP22 plays a role in cell 
differentiation were suggested by its repressive effect on 
SOX2 transcription in ESCs. It could be shown that USP22 
is required for differentiation of pluripotent stem cells into 
all three germ layers [34]. However, to date few studies have 
examined the role of USP22 in vivo. Lee et al. [35] described 
that Usp22 is ubiquitously expressed in adult murine tissues 
and at the early embryonic stages in the midbrain, forebrain, 
hindbrain and dorsal root ganglia. Genetic ablation of Usp22 
in mice resulted in early embryonal lethality at E10.5 of the 
post-implantation stage [22].
Here we describe the generation of a mouse model 
with a highly significant reduction of Usp22 expression 
levels. Using β-galactosidase staining we visualized 
ubiquitous activity of the Usp22 gene in most embryonic 
tissues. Adult mice with highly reduced Usp22 levels 
are viable but display a growth defect and reduction of 
body weight. We analyzed the small intestine as this 
organ represents an attractive model to study epigenetic 
regulatory processes due to its rapid turnover and its 
well characterized steps leading to tumorigenesis [36, 
37]. While the gross morphology of the small intestine 
was largely unaffected, detailed analyses suggest 
differentiation defects in the cells of the small intestine. 
Moreover, analysis of the brain of animals with reduced 
Usp22 expression confirmed a general importance for 
USP22 in differentiation in multiple organs.
RESULTS
Generation of Usp22lacZ mice and expression of 
Usp22
In order to characterize both the expression and 
function of Usp22, we generated a mouse line herein 
referred to as Usp22LacZ using a “knockout first” embryonic 
stem cell line (Usp22tm1a(KOMP)Wtsi C57Bl6) obtained from the 
University of California-Davis Knockout Mouse Project 
Repository. These mice have both a LacZ cassette as well as 
a neomycin resistance cassette inserted into the first intron 
of the Usp22 gene. Due to the presence of a splice acceptor 
site the LacZ gene is expressed under the control of the 
endogenous Usp22 promoter and enables the investigation 
of Usp22 gene activity in vivo (Figure 1a). Importantly, the 
resulting allele is predicted to result in the truncation of 
Usp22 expression due to the presence of polyadenylation 
sequences downstream of the LacZ and neomycin resistance 
genes, while leaving the Usp22 gene otherwise intact. Mice 
were backcrossed to the C57Bl6 background.
Usp22 has been reported to be expressed in several 
tissues in murine embryos and was shown to be highly 
present in the brain. However, only specific organs 
have been analyzed in embryos at E10.5 and E12.5 so 
far [35]. In order to visualize the expression pattern of 
Usp22 in more detail, embryos were processed for whole 
mount staining making use of the enzymatic activity of 
β-galactosidase which produces a characteristic blue 
staining upon cleavage of its substrate X-gal. At E10.5 
only Usp22lacZ/lacZ animals showed a strong LacZ staining 
of the skin at E10.5 (Figure 1b) while during development 
both Usp22wt/lacZ and Usp22lacZ/lacZ animals displayed strong 
lacZ expression in the skin (Figure 1c).
In order to investigate Usp22 expression in the 
inner organs at E15.5 in later development, embryos 
were cut sagittally and stained a second time (Figure 1d). 
Subsequently, paraffin sections were prepared and 
counterstained (Figure 1e, Table 1). Strong staining was not 
only detected in the skin but also in connective tissue and 
muscle. This was also observed in the facial region including 
tongue, lips and nasal cavity. In the brain, particularly 
strong staining was seen in the frontal lobe, cerebral cortex, 
subventricular zone and ganglionic eminences. Usp22 gene 
activity was only sporadically observed in cells of the mid- 
and hindbrain. In addition, the following organs displayed 
prominent Usp22 expression: heart, lung, kidneys, penis, 
thymus, bladder, pancreas, thyroid and intestine. In 
contrast, the liver did not display any detectable staining. 
Taken together, X-gal staining revealed ubiquitous Usp22 
expression in most embryonic tissues at E15.5. These 
findings corroborate the findings of a previous RNA-based 
study [35] and demonstrate pronounced Usp22 expression 
in the cerebral cortex, intestine and other internal organs 
during embryonic development.
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Figure 1: Generation of Usp22lacZ mice and expression of Usp22. a. Schematic overview of the Usp22lacZ mouse construct. The 
composition of the Usp22lacZ mouse construct is shown with exons indicated as black bars, untranslated regions as grey bars. The LacZ 
gene coupled to an EN2-SA-IRES sequence is expressed under the control of the endogenous Usp22 promoter. Selection of successfully 
recombined fragments is possible due to a neomycin resistance cassette under the control of human β-actin promoter. The decrease of Usp22 
expression is mediated by stop codons and poly-A sites behind the two cassettes in the construct. b–c. Usp22lacZ embryos at E10.5 and 
E15.5 have been stained for the presence of β-galactosidase activity using X-Gal as a substrate. During both developmental stages staining 
in the skin was observed. d–e. The same embryos at E15.5 as in c have been cut on a sagittal plane and stained again for β-galactosidase 
activity. Subsequently, pictures were taken from the embryos and from 20 μm sections. Paraffin sections have been counterstained. Scale 
bar: 2000 μm.
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Phenotype of adult Usp22lacZ mice
In contrast to a previous study reporting that ablation 
of Usp22 expression leads to embryonic lethality [22], 
Usp22lacZ mice were born with the expected Mendelian 
frequency. For our mouse cohorts Usp22wt/lacZ have been 
mated with each other. However, one mating with an 
Usp22lacZ/lacZ female was set up and offspring was obtained 
suggesting that animals with reduced Usp22 levels are 
fertile. Interestingly, Usp22lacZ/lacZ mice were, however, 
characterized by a clear growth retardation compared 
to their litter mates and their weight was reduced by 
40% at the age of 4 months (Figure 2a–2b). Since the 
intestine reflects an ideal disease-relevant model organ 
to study epigenetic regulatory mechanisms [36] and our 
β-galactosidase stainings revealed expression of Usp22 in 
both the cerebral cortex and the digestive tract, we aimed 
to examine the effects of Usp22 deficiency in vivo in 
both these organs in adult animals. Firstly we studied the 
expression of Usp22 in wildtype and Usp22lacZ/lacZ animals. 
Therefore, the brain and small intestines were isolated 
from 4 month-old Usp22lacZ mice and Usp22 expression 
levels were determined by qRT-PCR. Notably, while 
Usp22 expression in both organs of the Usp22lacZ/lacZ mice 
was significantly reduced, approximately 3% of correctly 
spliced mRNA levels were observed in mutant animals 
compared to their wild-type littermates (Figure 2c) 
indicating that the Usp22lacZ allele is hypomorphic. This 
was supported by an incomplete reduction of USP22 
protein levels in Western blot (Figure 2d).
Collectively, our findings show that, unlike the 
effects observed with a complete ablation of Usp22 
expression, a significant, but incomplete, reduction of 
Usp22 does not result in embryonic lethality, but rather 
leads to decreased body size and weight compared to their 
wild-type and heterozygous littermates.
Decreased Usp22 expression does not affect small 
intestine morphology
To investigate the role of USP22 in the small intestine 
we determined the effects of reduced Usp22 expression 
on the gross morphology and cellular content of the small 
intestine. Small intestine sections were stained with H&E 
and used for subsequent analyses. During all histological 
studies we carefully assessed proximal, intermediate 
as well as distal regions of the small intestine. Initially, 
villi length was measured and the mean values were 
calculated. When comparing Usp22wt/wt and Usp22lacZ/lacZ 
animals the mean length per villus was between 264 μm 
and 266 μm. We next counted approximately 2 crypts 
within a distance of 100 μm invariantly in all genotypes. 
Furthermore, the number of cells per crypt was between 
22 to 24 cells per crypt as estimated in at least 50 crypts 
per mouse (Figure 3a–3d). Taken together, these results 
revealed that the reduction of Usp22 expression does not 
alter the gross morphology of the small intestine.
The loss of Usp22 results in altered cellular 
composition in the small intestine
We next assessed the effects of Usp22 reduction 
on the cellular composition of the small intestine. Stem 
cells located near the bottom of crypts give rise to 
Table 1: Usp22-LacZ expression in the developing mouse embryo
Staining intensity Staining intensity
Front lobe +++ Tongue +++
Cerebellum ++ Thyroid ++
Neopallial cortex ++ Heart ++
Ventricular zone + Thymus ++
Midbrain + Lung +++
Hindbrain + Liver −
Olfactory lobe +++ Intestinal system +++
Spinal cord + Pancreas ++
Root ganglion +++ Kidneys +++
Nasal cavity +++ Bladder +++




+++ very strong staining
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four types of differentiated cells in the small intestine: 
Goblet cells, enteroendocrine cells, Paneth cells and 
enterocytes, which account for the majority of cells in 
the intestinal epithelium. We therefore tested whether 
Usp22 expression is required for the proper generation 
and distribution of differentiated cell types in villi and 
crypts. To assess the respective numbers of cell types, 
4 month old mice were sacrificed and respective cell 
populations were examined via immunohistochemical 
staining (Figure 4). To determine whether the number 
of stem cells was affected by Usp22 deficiency, we 
performed in situ hybridization analysis for the specific 
marker olfactomedin 4 (Olfm4) and observed a slight 
increase in the number of stem cells in the small 
intestines of Usp22lacZ/lacZ animals. To determine whether 
this change had an effect on the respective proportions 
of differentiated cells, immunochemistry was conducted 
for Goblet, enteroendocrine and Paneth cells using 
respectively staining against the specific markers Mucin 
2 (MUC2), Chromogranin A (CGA) and Lysozyme 
(LYZ). Goblet cells, responsible for mucus production 
in the small intestine, were counted in villi and crypts. 
The number of MUC2-positive cells in the crypts of 
Usp22lacZ/lacZ mice did not significantly differ compared 
Figure 2: Phenotype of adult Usp22lacZ mice. a. A representative image of Usp22lacZ animals at an age of 4 months shows growth 
retardation of Usp22lacZ/lacZ mice. b. The body weight of male Usp22lacZ/lacZ mice is reduced on average by 40% compared to their littermates. 
Mice have been weighed at an age of 4 months (wt/wt: n = 5; wt/lacZ: n = 9, p = 0.525; lacZ/lacZ: n = 6, p = < 0.0001). c. Relative mRNA 
expression of Usp22 in the small intestine (wt/wt: n = 4; wt/lacZ: n = 5, p = 0.007; lacZ/lacZ: n = 4, p = 8.10−4). d. Reduction of Usp22 
protein levels in brain and small intestine of Usp22lacZ/lacZ mice.
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to Usp22wt/wt mice. However, reduced levels of USP22 
led to a nearly 2-fold increase in the abundance of Goblet 
cells in villi.
Staining for CGA to detect hormone-producing 
enteroendocrine cells revealed about 50% and 45% 
more enteroendocrine cells in the crypts and villi of 
Usp22lacZ/lacZ animals, respectively. Paneth cells are 
located at the bottom of crypts. We found a clear 
increase of LYZ-positive cell frequency in the crypts of 
Usp22lacZ/lacZ mice (four to five cells per crypt) compared 
to wild-type animals (three Paneth cells per crypt). 
Thus, while the reduction of Usp22 expression did 
not affect the gross morphology of the small intestine, 
detailed analyses of the cellular composition suggests 
that proper intestinal epithelial cell differentiation in 
crypts and villi requires USP22 activity.
Figure 3: Expression of Usp22 at the crypt base does not affect small intestine morphology. a–d. Global reduction of Usp22 
levels does not lead to morphological changes of the small intestine. H&E-stained sections have been assessed regarding to villi length 
(wt/wt: n = 3; wt/lacZ: n = 3, p = 0.20; lacZ/lacZ: n = 3, p = 0.98), number of crypts per 100 μm (wt/wt: n = 3; wt/lacZ: n = 3, p = 0.85; 
lacZ/lacZ: n = 4, p = 0.65) and corresponding number of cells per crypt (wt/wt: n = 3; wt/lacZ: n = 3, p = 0.63; lacZ/lacZ: n = 3, p = 0.34). 
Regarding the morphology no significant differences were detected. Scale bar: 100 μm.
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Usp22 is required for proper differentiation in 
the adult mouse brain
To determine if the observed differentiation 
defect in Usp22-hypomorphic mice is restricted to 
the small intestine, or if this effect also occurs in 
other organs expressing high levels of Usp22, we 
examined the brains in adult Usp22lacZ mice. We first 
investigated the overall effects of reduced Usp22 
expression on the brain morphology by using Nissl 
and H&E stained brain sections. We observed that the 
gross morphology of the adult was mainly unaffected, 
but the cerebral cortex was smaller and less densely 
packed in animals with reduced Usp22 expression 
(Figure 5a–5b). This observation was in accordance 
with the expression pattern observed during forebrain 
development, which anticipated a potential cortical 
phenotype. We therefore analyzed further whether 
the loss of USP22 had an effect on the distribution of 
precursor or stem cells and differentiated neurons and 
on the layering of the cerebral cortex. We therefore 
examined the presence and number of progenitors 
Figure 4: The loss of Usp22 results in a differentiation shift in the small intestine. Reduction of Usp22 expression causes a 
slight increase in the number of olfactomedin 4 (OLFM4)-positive stem cells as revealed after in situ hybridization (wt/wt: n = 5; wt/lacZ: 
n = 4, p = 0.53; lacZ/lacZ: n = 5, p = 0.021). Immunohistochemistry shows an increase of differentiated cell types in the small intestine. 
The number of mucus-producing Goblet cells (Muc2) hardly varied in the crypts but was significantly increased in the villi (wt/wt: n = 5;  
wt/lacZ: n = 5, p = 0.69; lacZ/lacZ: n = 5, p = 0.023). A raised rate of enteroendocrine cells (CgA) was observed as well (wt/wt: n = 5; 
wt/lacZ: n = 5, p = 8.25.10–8; lacZ/lacZ: n = 5, p = 6.20.10–7). Paneth cells (Lyz) which are located at the bottom of the crypt show an 
increased presence in Usp22lacZ/lacZ animals (wt/wt: n = 3; wt/lacZ: n = 3, p = 0.15; lacZ/lacZ: n = 3, p = 0.017). Scale bar: 100 μm.
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of the subventricular zone as well as deep-layer and 
upper-layer neurons in adult wildtype and Usp22lacZ/lacZ 
animals by immunohistochemistry. Intermediate 
precursor cells (IPC) of the subventricular zone were 
stained with an antibody specific for T-box transcription 
factor 2 (TBR2) also known as Eomes. The localization 
and distribution of the IPC in the subventricular zone 
was similar when comparing Usp22wt/lacZ and Usp22lacZ/
lacZ animals (Figure 5c). Next, we determined whether, 
as seen in the intestinal epithelium, USP22 is required 
for the proper differentiation of glutamatergic neurons. 
Staining for a C2H2-type zinc finger protein (CTIP2) to 
detect differentiated early born deep-layer neurons and 
staining for special AT-rich sequence-binding protein 
2 (SATB2) to mark later born upper-layer neurons 
revealed a specification defect in Usp22lacZ/lacZ animals. 
Layer V-VI with the early born neurons appeared 
less densely packed, with fewer CTIP2 positive cells 
in Usp22lacZ/lacZ compared to Usp22wt/lacZ animals 
(Figure 5d). The later born neurons appeared more 
scattered within the cortical plate and were also less 
densely packed in USP22-depleted animals (Figure 5e). 
Taken together these results in the adult brain with the 
findings on the small intestine point at a role for USP22 
in lineage specification and differentiation of stem or 
precursor cells in different organ systems.
Effects of Usp22 knockout are independent of 
H2B monoubiquitination
Previous studies revealed that Usp22 is able to 
affect transcription by the deubiquitination of histone 
H2B [12–14]. To clarify whether this function mediates 
the impairment in differentiation observed in our studies, 
we assessed the levels of H2Bub1 and H2B (as a control) 
in Usp22lacZ mice. As revealed by Western blot analysis 
the global levels of H2Bub1 did not increase in the small 
intestine and brain of Usp22lacZ mice (Figure 6a). To 
ensure that H2B and H2Bub1 are still equally distributed 
over the entire small intestine IHC was carried out. Based 
on the number of positive cells and the staining intensity 
no apparent differences in H2B and H2Bub1 levels were 
detected (Figure 6b).
DISCUSSION
A previous study reported that the ablation of 
Usp22 expression results in embryonic lethality at 
E10.5 of the post-implantation stage [22]. In contrast, 
here we describe a mouse model with a significant 
global reduction in Usp22 levels which does not display 
embryonic lethality, but rather displays defects in cell 
fate determination in different tissues. The presence of 
LacZ and neomycin resistance cassettes downstream of 
the Engrailed splice acceptor site would be predicted 
to result in the termination of transcription. Our results 
show that Usp22lacZ mice still show a minimal level of 
residual expression of normally spliced Usp22 mRNA, 
which appears to be sufficient for the survival of these 
mice.
To date most studies related to Usp22 function 
have focused on its potential role in promoting 
stem cell-like characteristics in diverse tumor types, 
including colorectal cancer. Indeed, our results suggest 
that decreased Usp22 expression results in impaired 
differentiation in both the intestinal epithelium and in 
neurons in the cerebral cortex. Importantly, the role of 
USP22 during tumorigenesis is still largely unresolved. 
To date, most studies in patient samples were based 
either on microarray data or immunohistochemical 
analyses using antibodies whose specificity for USP22 is 
questionable. In our study we observe that, surprisingly, 
the gross morphology of the small intestine and the brain 
as well as the number of Olfm4-positive stem cells in 
Usp22-hypomorphic animals was largely unaffected, but 
rather a shift in the abundance of specific differentiated 
cell populations, i.e. Goblet and enteroendocrine cells, 
was increased or in post-mitotic neurons altered. This 
indicates that proper cell differentiation in the intestinal 
epithelium and the cerebral cortex is dependent on Usp22 
expression. However, whereas total cell numbers seem 
mostly unaffected in the small intestine, we observed 
fewer cells in the cerebral cortex. We conclude from 
this observation that although USP22 affects cell 
differentiation and/or lineage specification in general, 
its action might be under the control of organ specific 
cofactors responsible for context- or tissue-dependent 
phenotypes.
The results presented here provide important 
support that USP22 plays a central role in controlling 
lineage specification in vivo. Additional studies will 
be necessary to determine the molecular mechanisms 
by which it functions in these tissues. Our observations 
regarding differentiation could not be correlated to H2B 
and H2Bub1 levels suggesting that H2B is only partially 
deubiquitinated by Usp22. Moreover, a central question 
remains whether USP22 functions primarily as an 
epigenetic regulator, i.e., through its association with the 
SAGA complex, or whether other deubiquitination targets 
such as Sirt1 may be the central targets and mediators 
of USP22 function in vivo. Furthermore, tissue-specific 
ablation of Usp22 alone or in the context of mouse tumor 
models will be essential for determining its function both 
in individual tissues as well as in the context of tumor 
formation and progression. Overall, the findings presented 
here further support an important biological function of 
Usp22 and underscore the need for further in vivo and 
mechanistic studies to fully decipher its mechanisms of 




Generation of mice and genotyping
C57BL/6 embryonic stem cells expressing the LacZ 
gene under the control of the endogenous Usp22 promoter 
were obtained from the University-Davis Knockout Mouse 
Project Repository (clone Usp22_D11). Stop codons 
and poly-A sites result in a reduced Usp22 expression 
in these mice. Mice in this study were on the C57BL/6J 
background and used for analyses during embryonic stages 
or at an age to 3–4 months. Mice were genotyped by pre-
heating PCR samples to 95°C for 3 min. The respective 
DNA fragments were amplified in 35 polymerization 
cycles with 95°C for 30 s, 60°C for 30 s, 72°C for 1 min. 
It was allowed for a final elongation at 72°C for 10 min 
(wt fw: 5′- GTGCCCTGGTTGCCCAGTGAG -3′;lacZ 
fw: 5′- CCCAGCTTTCTTGTACAAAGTGGTT-3′; wt/
lacZ rv: 5′- CGGTTCAGGTGGATGCCGCA-3′).
RNA isolation
Snap-frozen tissue material was homogenized in 
TRIzol (Invitrogen) and RNA was extracted according to 
the manufacturer’s manual.
Quantitative real-time PCR
mRNA was reverse-transcribed using random 
hexameric and oligo-dT primers. SYBR Green 
(Invitrogen/Life Technologies) was used for qRT-PCR 
analysis with following primer sets. 189F: 5′-GGAG 
CCTGAGGTCGAGGCCA-3′ and 359R: 5′-ACACAG 
GACTTTGCCTTGCGC-3′, 189F and 373R: 5′-CAGCC 
GGTTCAGGTGGATGCC-3′, 211F: 5′-AACCGGCTGC 
ACTCTTGCCT-3′ and 410R: 5′-TTCCAAGCCTTG 
CGCTGCTCC-3′, 932F: 5′-GCCAAGTCTGCCACGG 
GGTC-3′ and 1061R: 5′-GGTGGTCCCGGATGCAT 
GGC-3′.
Figure 5: Loss of Usp22 in adult mouse brain results in impaired cortical differentiation. a–b. Usp22lacZ animals at an 
age of 4 months have been assessed regarding to morphological changes of the different brain regions. Sagittal Nissl and H&E-stained 
sections revealed a less densely packed cortex in mice with USP22 reduction. Scale bar: 500 μm. c–e. Immunohistochemistry shows 
less differentiated cells and impaired layering in the adult cerebral cortex on coronal sections. The morphology and distribution of the 
subventricular zone (SVZ) with its intermediate precursor cells (TBr2) appears normal. The layering of the deep-layer (CTIP2, layer V–VI) 
and upper-layer neurons (SATB2, layer II–IV) is impaired. Scale bar: 100 μm. CP: cortical plate, SVZ: subventricular zone, V: ventricle.
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X-gal staining of tissue
Tissues were collected and fixed (6.75 ml 37% 
formaldehyde, 2 ml 25% glutaraldehyde, 5 ml NP-40, 
25 ml 10x PBS, filled up to 250 ml with H2O, 110 mg 
DOC) on ice for 60 min. In the meanwhile, staining 
solution (2.5% 250 mM K3Fe(CN)6, 2.5% 250 mM 
K4Fe(CN)6, 2% 100 mM MgCl2 in PBS) was pre-
warmed to 37°C and X-gal solution (40 mg Xgal/ml 
Dimethylformamide) was added. After washing in PBS, 
tissues were incubated in staining solution in the dark 
for 24 h. Embryos were frozen in TissueTek and cut on 
the sagittal plane. The frozen embryos were thawn in 
0.1% PFA in PBS for approximately 10 min. Embryos 
were washed, dehydrated and prepared for paraffin 
embedding. After preparing 20 μm sections tissues have 
been counterstained using nuclear fast red-aluminum 
sulfate solution (Carl Roth).
Histology
For H&E staining sections were de-paraffinized, 
rehydrated and stained in hematoxylin (Merck). After 
rinsing counterstaining with Eosin (Carl Roth) was carried 
out until a sufficient staining was obtained. Nissl staining of 
brain sections was performed in 0.5% cresyl violet for 10 
min. The antigen retrieval for brain samples was performed 
by boiling sections in 0.2 M TBS pH 9.0. After blocking 
with 10% normal goat serum and 0.3% Triton X-100 in 
PBS, samples were incubated with primary antibodies 
in the blocking solution overnight at 4°C. The secondary 
antibodies were diluted in PBS and incubated for at least 
1 h at RT. The following antibodies were used: Satb2 
(Epitomics 2819-1, 1:100), Ctip2 (Abcam, ab18465, 1:200), 
Tbr2 (Millipore, Ab2283, 1:100). For immunohistochemical 
analysis of proteins in the small intestine sections antigen 
retrieval was performed by boiling slides in 10 mM citric 
Figure 6: Differentiation defect is independent of H2B and H2Bub1 levels. a. No difference in H2B and H2Bub1 levels was 
detected in protein samples isolated from Usp22lacZ small intestines and brains. b. Immunohistochemical staining of H2B and H2Bub1 
revealed that, regardless of the genotype, all cells are positively stained and show similar staining intensities (wt/wt: n = 4; wt/lacZ: n = 4; 
lacZ/lacZ: n = 4). Scale bar: 100 μm.
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acid/sodium-phosphate. Sections were quenched for 
endogenous peroxidases with 5% H2O2 in PBS and blocking 
was conducted using 10% fetal bovine serum (FBS) in PBS. 
Primary antibodies for Mucin 2 (Santa Cruz, sc-15334, 
1:200), Lysozyme (Abcam, ab36362, 1:200),Chr-A (Santa 
Cruz, sc-13090, 1:200), H2B (Abcam, ab1790, 1:1000) and 
H2Bub1 ([7], 1:20) were diluted in PBS containing 10% 
FBS and incubated overnight at 4°C. Biotinylated secondary 
antibodies were diluted 1:200. Sections were incubated 
with ExtrAvidin-Peroxidase (Sigma) diluted 1:1000 in PBS 
the staining was developed using DAB (Immpact™ DAB 
Peroxidase Substrate Kit SK-4105 [Vector]). Hematoxylin 
was used for counterstaining. 100–200 crypts or villi were 
counted per small intestine section obtained from at least 4 
mice per genotype.
In situ hybridization
pBlue Olfm4 plasmid has been linearized overnight. 
For the in vitro transcription using a DIG RNA labeling kit 
(Roche), two reactions have been set up each with 2 μg of 
linearized plasmid DNA. Mixtures have been incubated at 
37°C for 4 h and RNA was subsequently purified. An equal 
volume of formamide was added and stored at −20°C. 9 
μm thick paraffin sections of the small intestine have been 
deparaffinized and rehydrated. Slides were incubated in 0.2 
N HCl for 15 min. After rinsing with DEPC-treated water, 
sections were treated with Proteinase K (Invitrogen) in PBS 
for 20 min which has been pre-warmed to 37°C. Slides were 
rinsed in 0.2% glycine in PBS and PBS to stop the reaction. 
Sections have been post-fixed in 4% PFA for 10 min. Slides 
were incubated in PBS and 5x SSC buffer (750 mM NaCl, 
75 mM Na3C6H5O7.2H2O in H2O) for 5 min each. Sections 
were pre-hybridized by adding 400 μl hybridization solution 
per slide and stored at 68°C h in a humid chamber containing 
a 5x SSC/formamide mixture (1:1) for 1 h. Prehybridization 
solution was replaced with hybridization solution containing 
500 ng/ml DIG-labelled OLFM4 RNA probe. Slides were 
incubated at 68°C for approximately 90 h.
Slides were rinsed twice in 2x SSC (pH 4.5) and 
washed in triplicate with 50% formamide/2x SSC 
(pH 4.5) at 63°C for 20 min. After rinsing in 5x TBS-T, 
slides were incubated in blocking solution (0.5% blocking 
powder [Roche] in TBS-T) at room temperature for 2 h. 
Anti-DIG Fab (Roche, 11093274910) was diluted 1:2000 
in blocking solution and incubated at 4°C overnight. 
Slides were rinsed five times in TBS-T and three times 
in NTM buffer (100 mM NaCl, 100 mM Tris, 50 mM 
MgCl2, in H2O). Staining was developed by incubation 
in NBT/BCIP solution (10 ml NTM buffer, 333 μl NBT 
solution (10 mg tablet dissolved in 1 ml H2O), 35 μl BCIP 
(25 mg tablet dissolved in 500 μl dimethylformamide), 
25 μl 1 M levamisole) until blue staining could be 
observed. Subsequently slides were rinsed in NTM buffer, 
dehydrated and embedded as described above. Positive 
cells localized in 100–200 crypts have been counted.
Western blot
For Western blot analysis brains and small 
intestines were lysed in RIPA buffer (1% NP-40, 0.5% 
sodium deoxycholate and 0.1% SDS in PBS) containing 
1 mm N-ethylmaleimide, 1 mm Pefabloc and 1 μg/ml 
Aprotinin/Leupeptin. Proteins were separated by SDS–
polyacrylamide gel electrophoresis and transferred to a 
nitrocellulose membrane. Proteins were detected using 
antibodies against Usp22 (Santa Cruz, sc-390585), H2B 
(Abcam, ab1790), H2Bub1 ([7]), GAPDH (Abcam, 
ab8245) and β-actin (Abcam, ab8227) and horseradish 
peroxidase-conjugated secondary antibodies (Santa Cruz).
Statistical analyses
All graphs in this study have been designed with 
GraphPad Prism version 5.04 (GraphPad Software, Inc.). 
P-values were determined using Student’s t-test.
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